INDIANAPOLIS, Oct. 12 /PRNewswire/ -- Premier Inc., the nation’s largest healthcare alliance, gave its 1,700 hospital members access in August to the Roche COBAS(R) Ampliprep/COBAS(R) TaqMan(R) HIV-1 assay -- the only real-time PCR test for HIV offered to its members.
Premier added the new HIV-1 monitoring test, COBAS(R) TaqMan(R) 48 Analyzer and COBAS(R) TaqMan(R) Analyzer to its existing three-year molecular contract so that customers could combine the COBAS(R) Ampliprep, which was included in the existing molecular contract, with the COBAS(R) TaqMan(R) and the docking station to experience full automation.
“Adding the Roche HIV-1 monitoring test to Premier’s menu is consistent with our mission to quickly roll out the highest level of innovation to our customers,” said John Biggers, Group Vice President of Sourcing at Premier. “Premier also added COBAS(R) Taqman(R) 48 Analyzer, COBAS(R) Taqman(R) Analyzer and Roche’s unique docking station so that customers could take advantage of the test’s full automation while offering to their patients the most advanced HIV-1 monitoring assay based on 11 years of experience in HIV monitoring.”
Roche introduced the fully automated COBAS(R) Ampliprep/COBAS(R) TaqMan(R) in response to customers’ needs for a system that could allow their molecular laboratory technicians to load samples and walk away, not returning until the sample results are ready.
“Molecular technicians are in high demand,” said Susan Zienowicz, Vice President for Molecular Diagnostics of Roche Diagnostics. “In creating the COBAS(R) Ampliprep/COBAS(R) TaqMan(R) HIV-1 assay, we provide labs with another strategy to help them leverage their employees’ time and get more done in the lab.”
About Premier Inc.
Serving 1,700 hospitals and more than 47,000 other healthcare sites, Premier is the largest healthcare alliance in the United States dedicated to improving patient outcomes while safely reducing the cost of care. Owned by not-for profit hospitals, Premier operates the nation’s largest healthcare purchasing network, the most comprehensive repository of hospital clinical and financial information and one of the largest policy-holder owned, hospital professional liability risk-retention groups in healthcare. Headquartered in San Diego, Premier has offices in Charlotte, N.C. Philadelphia and Washington. For more information, visit www.premierinc.com.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our Web site www.roche-diagnostics.us.
All trademarks used or mentioned in this release are legally protected by law.
lori.mclaughlin@roche.com
CONTACT: Lori McLaughlin, Corporate Communications, +1-317-521-3112,
lori.mclaughlin@roche.com, of Roche Diagnostics
Web site: http://www.roche.com/
http://www.roche-diagnostics.us/
http://www.premierinc.com/
